Project Grant HT94252410118
Award Date
4/1/24
Completion Date
8/31/26
Dollars Obligated
$1.4M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Natick, MA 01760, USA
Similar Awards
This Project Grant award, in the amount of $659,922.00, was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development federal grant program (CFDA 12.420). The award will fund a gene therapy research project at Macquarie University in Australia to develop a pathway for delaying the onset of neurodegenerative diseases like Amyotrophic Lateral Sclerosis (ALS) through nuclear TDP-43 supplementation. The project will run from September 15, 2025 to September 14,...
This Project Grant award of $2,163,115.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by Pathmaker Neurosystems Inc. to develop a noninvasive neuromodulation approach to slow the progression of amyotrophic lateral sclerosis (ALS) by suppressing neuronal hyperexcitability. The research, taking place in Boston, MA, aims to explore this innovative therapeutic method over the 2-year performance period...
This $854,060 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) was provided to Formation Venture Engineering Foundry Inc., a for-profit biotech firm, to develop an FC-fusion protein active vaccine for the prevention and treatment of C9ORF72 ALS/FTD, a rare neurodegenerative disease. The award period is from Apr 15, 2024 to Apr 14, 2026. The Military Medical Research and Development program supports innovative biomedical research...
The federal Project Grant award for $1,979,313.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports Sachi Bioworks, Inc. in the development of a novel brain-penetrant RNA therapeutic for the treatment of amyotrophic lateral sclerosis (ALS). Sachi Bioworks, a self-certified small disadvantaged business based in Erie, Colorado, will utilize its proprietary NanoligomerTM technology platform to create this innovative...
This federal Project Grant award of $911,151.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the development of PEG10 inhibitors for the fight against ALS-FTD. The award, with a performance period from February 15, 2025 to February 14, 2027, is being provided to The Regents of the University of Colorado, which is conducting the research through its Office of Contracts and Grants. The project aims to explore innovative...
This federal Project Grant award, valued at $1,103,084.00, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The funding supports the development of a personalized blood-based diagnostic assay for early detection of Amyotrophic Lateral Sclerosis (ALS) at Arizona State University. The university will collaborate with a sub-awardee, Georgetown University, to conduct the research. The project aims to transform healthcare for...
The Defense Health Agency awarded a $929,948 Project Grant to The Washington University in St. Louis, Missouri to support the research project "TARGETING TDP-43 MITOCHONDRIAL MISLOCALIZATION IN ALS". This grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research aimed at improving the health and care of military service members, veterans, and their families. The research project will investigate mitochondrial...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $796,875 project grant to the University of Florida (UF) Division of Sponsored Research. The grant, awarded on April 1, 2024, supports the development of heterobifunctional degraders of TDP-43 as a novel therapeutic strategy for amyotrophic lateral sclerosis (ALS). Under this grant, the University of North Carolina at Chapel Hill (UNC-CH) Office of Sponsored Research is serving as a sub-awardee....
This federal Project Grant award of $1,072,079.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research by the Massachusetts Institute of Technology (MIT) to develop diagnostic biomarkers for clinical subtypes of amyotrophic lateral sclerosis (ALS). The research aims to advance the understanding and treatment of ALS, a neurological disorder, with potential benefits for military service members and the broader public....
The Defense Health Agency awarded a $1.19 million Project Grant to The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. from May 1, 2023 to April 30, 2026 under the Military Medical Research and Development program (CFDA 12.420). The grant funds research into targeting excessive sphingolipid synthesis for treatment of amyotrophic lateral sclerosis (ALS) being conducted by Dr. Teresa M. Dunn of the Uniformed Services University of the Health Sciences. Dr. Dunn is...